The Mumbai-based pharmaceutical company Glenmark will soon be opening its $100 million plant in Monroe, North Carolina. The conglomerate decided to locate to the U.S. on the heels of an FDA crackdown on Indian prescription drug exports.
The facility will employ 168 workers from the outset, but Glenmark expects that number to rise. According to Fierce Pharma, the 100,000-square-foot facility is primed to produce fixed dose formations in capsules and tablets, vials, pre-filled syringes and inhalable ampoules.
Glenmark won its first Abbreviated New Drug Application for the Monroe, North Carolina, plant this past June.